Pre-made Aducanumab benchmark antibody ( Whole mAb, anti-APP therapeutic antibody, Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Aducanumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Aducanumab, sold under the brand name Aduhelm, is used to treat Alzheimer's disease (AD). It is an amyloid beta-directed monoclonal antibody.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-011-1mg	1mg	3090
GMP-Bios-ab-011-10mg	10mg	Inquiry
GMP-Bios-ab-011-100mg	100mg	Inquiry
GMP-Bios-ab-011-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Aducanumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
INN Name	Aducanumab
Target	APP
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	6cnr:HL/6co3:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Biogen;Neurimmune
Conditions Approved	Alzheimer's disease
Conditions Active	na
Conditions Discontinued	na
Development Tech	na